{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:51:31Z","timestamp":1790887891778,"version":"4.1.0"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UNITAID","award":["N\/A FIND"],"award-info":[{"award-number":["N\/A FIND"]}]},{"name":"Netherlands Government","award":["N\/A FIND"],"award-info":[{"award-number":["N\/A FIND"]}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Globally, there are approximately 58 million people with chronic hepatitis C virus infection (HCV) but only 20% have been diagnosed. HCV self-testing (HCVST) could reach those who have never been tested and increase uptake of HCV testing services. We compared cost per HCV viraemic diagnosis or cure for HCVST versus facility-based HCV testing services. We used a decision analysis model with a one-year time horizon to examine the key drivers of economic cost per diagnosis or cure following the introduction of HCVST in China (men who have sex with men), Georgia (men 40\u201349 years), Viet Nam (people who inject drugs, PWID), and Kenya (PWID). HCV antibody (HCVAb) prevalence ranged from 1%-60% across settings. Model parameters in each setting were informed by HCV testing and treatment programmes, HIV self-testing programmes, and expert opinion. In the base case, we assume a reactive HCVST is followed by a facility-based rapid diagnostic test (RDT) and then nucleic acid testing (NAT). We assumed oral-fluid HCVST costs of $5.63\/unit ($0.87-$21.43 for facility-based RDT), 62% increase in testing following HCVST introduction, 65% linkage following HCVST, and 10% replacement of facility-based testing with HCVST based on HIV studies. Parameters were varied in sensitivity analysis. Cost per HCV viraemic diagnosis without HCVST ranged from $35 2019 US dollars (Viet Nam) to $361 (Kenya). With HCVST, diagnosis increased resulting in incremental cost per diagnosis of $104 in Viet Nam, $163 in Georgia, $587 in Kenya, and $2,647 in China. Differences were driven by HCVAb prevalence. Switching to blood-based HCVST ($2.25\/test), increasing uptake of HCVST and linkage to facility-based care and NAT testing, or proceeding directly to NAT testing following HCVST, reduced the cost per diagnosis. The baseline incremental cost per cure was lowest in Georgia ($1,418), similar in Viet Nam ($2,033), and Kenya ($2,566), and highest in China ($4,956). HCVST increased the number of people tested, diagnosed, and cured, but at higher cost. Introducing HCVST is more cost-effective in populations with high prevalence.<\/jats:p>","DOI":"10.1371\/journal.pgph.0001667","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:37:04Z","timestamp":1680716224000},"page":"e0001667","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-effectiveness of Hepatitis C virus self-testing in four settings"],"prefix":"10.1371","volume":"3","author":[{"given":"Josephine G.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad S.","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippa","family":"Easterbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Fajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl Case","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Luhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fern","family":"Terris-Prestholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1569-8758","authenticated-orcid":true,"given":"Sonjelle","family":"Shilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"pgph.0001667.ref001","volume-title":"Towards ending viral hepatitis","author":"World Health Organization","year":"2016"},{"key":"pgph.0001667.ref002","article-title":"Second round of the national pulse survey on continuity of essential health services during the COVID-19 pandemic","author":"World Health Organization","year":"2021","journal-title":"Interim report"},{"issue":"1","key":"pgph.0001667.ref003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"S Blach","year":"2021","journal-title":"J Hepatol"},{"key":"pgph.0001667.ref004","author":"World Health Organization","year":"2017"},{"issue":"1","key":"pgph.0001667.ref005","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.jhep.2016.08.002","article-title":"Guidelines Development Group. Who to test and how to test for chronic hepatitis C infection\u20142016 WHO testing guidance for low- and middle-income countries","volume":"65","author":"WHO Easterbrook PJ","year":"2016","journal-title":"J Hepatol"},{"key":"pgph.0001667.ref006","volume-title":"Recommendations and guidance on hepatitis C virus self-testing","author":"World Health Organization","year":"2021"},{"key":"pgph.0001667.ref007","volume-title":"Recommendations and guidance on hepatitis C virus self-testing","author":"World Health Organization","year":"2021"},{"key":"pgph.0001667.ref008","volume-title":"Recommendations and guidance on hepatitis C virus self-testing","author":"World Health Organization","year":"2021"},{"key":"pgph.0001667.ref009","article-title":"Demographic Situation in Georgia (2019).","year":"2020","journal-title":"National Statistics Office of Georgia"},{"issue":"15","key":"pgph.0001667.ref010","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0000000000003382","article-title":"Modelling the Impact of HIV and hpatitis C virus prevention and treatment interventions among people who inject drugs in Kenya","volume":"36","author":"J Stone","year":"2022","journal-title":"AIDS"},{"issue":"5","key":"pgph.0001667.ref011","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1071\/SH22010","article-title":"A community-based organisation-led HIV self-testing program among men who have sex with men in China is cheaper and more effective than facility-based HIV testing: an economic evaluation","volume":"19","author":"SZ Huang","year":"2022","journal-title":"Sex Health"},{"key":"pgph.0001667.ref012","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.drugalcdep.2017.11.033","article-title":"Using dual capture\/recapture studies to estimate the population size of persons who inject drugs (PWID) in the city of Hai Phong, Vietnam.","volume":"185","author":"D Des Jarlais","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl 3","key":"pgph.0001667.ref013","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12889-019-6784-3","article-title":"Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination","volume":"19","author":"LM Hagan","year":"2019","journal-title":"BMC Public Health"},{"issue":"11","key":"pgph.0001667.ref014","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S1473-3099(19)30264-6","article-title":"Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study","volume":"19","author":"MJ Akiyama","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"pgph.0001667.ref015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S2468-1253(20)30303-4","article-title":"Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis","volume":"6","author":"F Jin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"pgph.0001667.ref016","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1038\/s41598-020-63990-w","article-title":"HIV control programs reduce HIV incidence but not HCV incidence among people who inject drugs in HaiPhong, Vietnam","volume":"10","author":"JP Moles","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"pgph.0001667.ref017","doi-asserted-by":"crossref","first-page":"e039234","DOI":"10.1136\/bmjopen-2020-039234","article-title":"Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).","volume":"10","author":"D Rapoud","year":"2020","journal-title":"BMJ Open"},{"issue":"4","key":"pgph.0001667.ref018","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2019.11.019","article-title":"Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia","volume":"72","author":"F Averhoff","year":"2020","journal-title":"J Hepatol"},{"issue":"2","key":"pgph.0001667.ref019","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/add.15630","article-title":"An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis","volume":"117","author":"N Mafirakureva","year":"2022","journal-title":"Addiction"},{"key":"pgph.0001667.ref020","author":"World Health Organization","year":"2019"},{"issue":"Suppl 1","key":"pgph.0001667.ref021","doi-asserted-by":"crossref","first-page":"e25255","DOI":"10.1002\/jia2.25255","article-title":"Economic cost analysis of door-to-door community-based distribution of HIV self-test kits in Malawi, Zambia and Zimbabwe.","volume":"22","author":"C Mangenah","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"pgph.0001667.ref022","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/liv.15431","article-title":"Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.","volume":"43","author":"I Tskhomelidze","year":"2023","journal-title":"Liver International."},{"issue":"9","key":"pgph.0001667.ref023","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.jval.2020.03.018","article-title":"Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam","volume":"23","author":"OT Due","year":"2020","journal-title":"Value Health"},{"key":"pgph.0001667.ref024","article-title":"Sensitivity and specificity of rapid diagnostic tests for hepatitis C virus with or without HIV coinfection: a multicentre laboratory evaluation study","author":"BN Vetter","year":"2020","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"pgph.0001667.ref025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1186\/s12879-017-2773-2","article-title":"Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature","volume":"17","author":"W Tang","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pgph.0001667.ref026","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/infdis\/jiv040","article-title":"Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries","volume":"212","author":"V Cambiano","year":"2015","journal-title":"J Infect Dis"},{"issue":"4","key":"pgph.0001667.ref027","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/liv.15191","article-title":"Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three-arm study","volume":"42","author":"S Shilton","year":"2022","journal-title":"Liver International"},{"key":"pgph.0001667.ref028","unstructured":"The Global Fund to Fight AIDS Tuberculosis and Malaria. Price & Quality Reporting Price Reference Report 2021 [Available from: https:\/\/www.theglobalfund.org\/en\/sourcing-management\/price-quality-reporting\/]."},{"key":"pgph.0001667.ref029","article-title":"Consumer price index (2010 = 100).","author":"World Bank","year":"2020"},{"issue":"1","key":"pgph.0001667.ref030","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/s12889-022-13125-9","article-title":"Protocol for a cluster randomised controlled trial of secondary distribution of hepatitis C self-testing within the context of a house-to-house hepatitis C micro-elimination programme in Karachi, Pakistan.","volume":"22","author":"S Shilton","year":"2022","journal-title":"BMC Public Health"},{"issue":"1","key":"pgph.0001667.ref031","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13063-022-06230-y","article-title":"A quasi-randomised controlled trial of online distribution of home-based hepatitis C self-testing for key populations in Malaysia: a study protocol","volume":"23","author":"S Shilton","year":"2022","journal-title":"Trials"},{"issue":"9","key":"pgph.0001667.ref032","doi-asserted-by":"crossref","first-page":"e056243","DOI":"10.1136\/bmjopen-2021-056243","article-title":"Home-based hepatitis C self-testing in people who inject drugs and men who have sex with men in Georgia: a protocol for a randomised controlled trial","volume":"12","author":"S Shilton","year":"2022","journal-title":"BMJ Open"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0001667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T17:37:38Z","timestamp":1680716258000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0001667"}},"subtitle":[],"editor":[{"given":"Alice","family":"Zwerling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0001667","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]}}}